Two industry accounts detailed rapid proliferation of gene‑editing modalities and a banner year for in vivo gene therapies. One piece chronicled the expanding toolkit of editing technologies and the ongoing search for a broadly curative approach; another reviewed 2025’s advances in delivery and preclinical progress that propelled multiple in‑vivo programs toward clinical proof‑of‑concept. Companies and academic groups are pursuing diverse editing chemistries and delivery vectors to overcome tissue tropism and immune barriers. The view from industry practitioners is that incremental advances in specificity, delivery and safety in 2025 materially shortened timelines for clinical translation in several disease areas. For readers: 'in vivo' gene therapy refers to delivering gene‑editing or gene‑replacement cargo directly into a patient rather than ex vivo manipulation of cells. Watch for IND filings, safety readouts and platform consolidation as the field moves from preclinical promise to clinical validation.